SHANGHAI, March 5th, 2026 —— AI technology is deeply penetrating the entire drug R&D value chain, and China's AI drug discovery industry is standing at a critical juncture of transitioning from "tool output" to "value validation". Against this backdrop, the capital market is increasingly focusing on identifying high-potential players in the sector.
Recently, Luke Liu, Partner of CIC, shared in-depth judgments on the development trends of AI drug discovery enterprises in an exclusive interview with Cailian Press.
Here are the key takeaways from the interview:
China's Unique Path in AI Drug Discovery
According to Luke, China's AIDD landscape possesses distinct characteristics that shape its long-term trajectory. "China has strong early-stage R&D and clinical resources, making it well-suited to embed AI into a closed loop of 'design-synthesize-screen-translate,' offering advantages in algorithm iteration speed and cost," he explained.
While many domestic companies currently operate by selling AI tools as a service, a notable shift is underway. A growing number of leading firms are beginning to use products or clinical results as their deliverable. They are securing cash flow and anchoring valuations through out-licensing deals, joint development agreements, and business models combining platform service fees with milestone payments.
2025: A Year of Divergence and Tangible Proof Points
Analyzing key industry metrics from 2025, Luke highlighted a crucial change in the funding environment. "Overall financing warmed up in 2025, but it presented a clear picture of divergence," he noted. The market is now placing a premium on AIDD companies that can demonstrate strong performance on "hard metrics" and "deliverable indicators." These include:
Proven improvements in drug-likeness.
Reduced experimental turnaround times.
High efficiency in producing Preclinical Candidate Compounds (PCCs).
More significantly, some AIDD companies have now successfully licensed specific molecular assets to major international pharmaceutical companies. This achievement, Luke emphasized, marks the industry's crucial step from being a conceptual tool to delivering tangible products.
Opportunities and Challenges on the Horizon for 2026
Looking ahead to 2026, Luke outlined the key opportunities and challenges that will define the next phase for AIDD companies.
Opportunities will center on the implementation of multimodal and foundational biology models. By enabling more efficient design, these advanced AI models can further boost R&D productivity, accelerating both molecule development and the pace of business development (BD) transactions.
The primary challenge lies in the subsequent clinical data validation following molecule development. The ultimate proof of value for AI-discovered molecules rests on their ability to successfully pass clinical trials and gain regulatory approval for commercialization.
Core Competencies for Long-Term Value Creation
Given this environment, Luke identified four critical traits that will distinguish AIDD companies worthy of sustained capital market attention:
Integrated Wet-Dry Lab Capability: The ability to rapidly validate AI models through iterative, closed-loop experimentation.
Robust Data Assets and Governance: A systematic framework to continuously generate effective, high-quality molecules at scale.
Global BD Capability: A proven track record of out-licensing AI-discovered drug assets to international partners.
Commercialization Prowess: A dual-engine model that advances both partnered programs and proprietary pipelines toward commercialization.
As the industry moves decisively from promise to proof, these capabilities will separate the leaders from the rest in the race to bring AI-powered drugs to patients.
Part of the views in this article were published in Cailian Press: AI Pharma: 130% Surge in Financing—Can the Promise Become Realit?
Cailian Press Report: Shi Shiyun; Executive Editor: Xu Hong
About CIC
CIC is a professional consulting firm offering tailored end-to-end support across the full investment and financing lifecycle. The firm boasts a world-leading track record in guiding landmark first-in-sector IPOs across global markets, alongside unrivaled reach and in-depth coverage capabilities across specialized niche market segments.
CIC helps enterprises refine scalable business models and craft compelling capital narratives to enable seamless access to global capital markets, while serving as a trusted due diligence partner to investment institutions. It delivers granular industry insights and direct access to subject matter experts, empowering clients to identify high-value opportunities and mitigate critical risks effectively.
Media Contact
marketing@cninsights.com